Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom

Journal of Health Economics and Outcomes Research
Gaurav SuriRohit Mistry

Abstract

To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2-) advanced breast cancer from a UK payer perspective. A cohort-based partitioned survival model was developed to evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with HR+/HER2- advanced breast cancer over a lifetime horizon. The analysis was carried out from a National Health Services and Personal Social Services perspective, and results are presented in incremental costs per quality adjusted life years. Clinical data from three randomized controlled trials (MONALEESA-2, PALOMA-1 and PALOMA-2 studies) were used, and supplemented with available real world evidence. Costs categories comprised of drug acquisition, medical management, and treatment of adverse events. Healthcare resource utilization data were identified from literature and unit costs sourced from secondary sources. Utility values were derived from MONALEESA-2 study and were supported with values identified from literature. Both deterministic and probabilistic analyses were carried out to...Continue Reading

References

Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Sep 8, 2000·PharmacoEconomics·A H Briggs
Sep 13, 2006·British Journal of Cancer·A LloydJ Watkins
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everardo D SaadMarc Buyse
Aug 25, 2010·Current Medical Research and Opinion·Michael LipsitzAmy Guo
Jan 24, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Nicholas R Latimer
Feb 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Miguel MartínJuan R De la Haba-Rodriguez
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Aug 24, 2017·Health Economics·Nancy J DevlinBen van Hout
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo

❮ Previous
Next ❯

Citations

Oct 22, 2020·Expert Review of Anticancer Therapy·Patrick NevenGuy Jerusalem

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01958021
NCT00721509
NCT01740427

Software Mentioned

Excel®
MONALEESA

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.